Sino Biological Inc.

Sino Biological, Inc. ("Sino Biological" or the "Company”), a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext (SZSE: 301047), specializing in biological research reagents and related technical contract research services, has successfully concluded the acquisition of Vancouver-based Canadian biotechnology company SignalChem Biotech Inc. ("SignalChem” or “SCB”). Sino Biological has acquired 100% of SignalChem shares in a deal valued at $48M USD, inclusive of all assets, assumed indebtedness, and net of cash deposits, underscoring the company’s dedication to advancing the life sciences industry. SignalChem is renowned for its specialized bioactive enzymes, including kinases, proteases, phosphatases, ubiquitin and epigenetic enzymes, and offers tailored contract research services ranging from enzyme development and compound profiling to assay development. Over the past two decades, SignalChem has established proprietary production and quality control platforms, setting industry standards for the development and production of high-quality bioactive enzyme proteins to support scientists from basic research through drug discovery and development. Now operating as a wholly-owned subsidiary of Sino Biological, SignalChem will bring exclusive expertise in enzyme production to the company’s existing technology platforms. “SignalChem is at the scientific forefront of enzyme bioreagent development and production, as well as enzyme-based compound screening technologies. The acquisition of SignalChem further strengthens Sino Biological’s robust presence in bioactive recombinant proteins and related contract research services,” stated Dr. Jie Zhang, Sino Biological’s President and General Manager. "We are excited to join forces with Sino Biological and embark on this new chapter of growth and collaboration," said Mr. Jun Yan, co-founder, president, and CEO of SignalChem. "Together, we have a unique opportunity to leverage our complementary strengths and resources to accelerate innovation and better serve the scientific community. We look forward to combining our expertise to develop novel solutions that address the complex challenges facing researchers around the world.” Sino Biological remains committed to maintaining the high standards of quality, reliability, and customer satisfaction throughout the integration process. Sino Biological will continue investing in research and development to maintain its leadership in the field. Customers can expect continued access to the same high-quality products and services they have come to rely on, backed by the combined expertise and resources of Sino Biological and SignalChem. The strategic synergy between Sino Biological and SignalChem enables the provision of a broader range of products and research services, supporting the wider life sciences community and facilitating the discovery and development of novel treatments, vaccines and diagnostic platforms. “We're thrilled to announce this major milestone in our journey to expand the product offering and service capabilities: SignalChem is now part of the Sino Biological family,” stated Dr. Rob Burgess, Chief Business Officer of Sino Biological. “This union marks a significant step forward in Sino Biological's commitment to bolstering its global footprint and revolutionizing the biotech industry, offering scientists even more innovative solutions for their research needs.” Forward-Looking Statements Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on Sino Biological and SCB management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, over which neither Sino Biological nor SCB has control. Sino Biological and SCB assume no obligation to update these forward-looking statements and do not intend to do so. Contacts: Sino Biological, Inc. gmo@sinobiological.cn

On July 9th, 2024, the U.S. FDA approved Arcutis Biotherapeutics' ZORYVE® (roflumilast) for treating atopic dermatitis (AD), the most common type of eczema affecting millions in the U.S. This once-daily, steroid-free cream could become a new standard of care for AD. The approval underscores the growing importance of researching Phosphodiesterase 4 (PDE4) and other PDEs as immunomodulatory targets for various inflammatory diseases. Sino Biological, and its subsidiary SignalChem Biotech, support drug discovery and development targeting PDEs by providing a broad range of PDE families and isoforms. Mechanism of Action Roflumilast is a phosphodiesterase-4 (PDE4) inhibitor that reduces inflammation by increasing cyclic adenosine monophosphate (cAMP) levels, an important molecule in regulating inflammation. PDE4, which breaks down cAMP, has four subtypes (PDE4A, PDE4B, PDE4C, PDE4D) and about 20 isoforms. The anti-inflammatory effects of PDE4 inhibitors are mainly due to inhibiting PDE4B and PDE4D, which are highly expressed in immune cells. By inhibiting these subtypes, roflumilast raises cAMP levels, decreasing pro-inflammatory mediators (e.g., TNF alpha, IL-4, IL-5, IL-13, IL-17A, IL-17F, IL-22) and increasing the anti-inflammatory mediator IL-10. This helps manage inflammatory conditions like atopic dermatitis, alleviating symptoms such as redness, itching, and swelling. PDE4 inhibitors mechanism of action. DOI:10.1517/13543784.2015.1094054 Phosphodiesterases (PDEs) as drug targets PDE enzymes control essential body functions by managing cAMP and cGMP levels. Various PDE inhibitors are developed for diseases: PDE1/2 for cardiovascular and neurological disorders; PDE4 for COPD and atopic dermatitis; PDE5 for erectile dysfunction and pulmonary arterial hypertension; PDE6 for retinal diseases; and PDE7 for inflammatory and autoimmune problems. In summary, PDE inhibitors are powerful tools and hold great promise as drug targets for wide-ranging therapeutic applications. Sino Biological’s Offering to Support Phosphodiesterases (PDEs) Research Sino Biological, along with its subsidiary SignalChem Biotech, is at the forefront of advancing drug development, offering a wide variety of recombinant PDE families and isoforms, to facilitate research on PDEs. Partner with us and visit our website to learn more about how we can best work together to accelerate the PDEs research.

On April 29th, 2024, the U.S. FDA granted full approval for Seagen Inc.'s TIVDAK® (tisotumab vedotin) targeting tissue factor (TF) for the treatment of patients with recurrent or metastatic cervical cancer who have progressed on or after chemotherapy. This marks a significant advancement in the therapeutic landscape for cervical cancer, highlighting the potential of antibody-drug conjugates (ADCs) in oncology. TIVDAK’s Mechanism of Action Tivdak is an ADC drug that targets TF, combining Genmab's TF-targeting monoclonal antibody tisotumab with Seagen's ADC technology, which is designed to target TF antigens on cancer cells and deliver the cytotoxic payload MMAE directly into cancer cells. Tisotumab Vedotin molecular pathway of action ( ) TF: ideal target for ADC development TF is known to be involved in tumor signaling and angiogenesis pathways and overexpressed in the vast majority of patients with cervical cancer and in many other solid tumors. Its ability to internalize rapidly when bound by antibodies and the minimal impact on normal coagulation processes further enhance its suitability for targeted cancer therapies. Sino Biological’s Contribution to Tissue Factor Drug Development Sino Biological is at the forefront of advancing drug development targeting tissue factor, providing an extensive array of recombinant TF proteins and a diverse range of TF antibodies, to support the scientific community in pioneering new therapeutic strategies. Partner with Sino Biological and visit our website for further information about high-quality TF proteins and antibodies to accelerate your drug development.